Evidence map›Paper›PMID 31598136›Full record

ArticleTherapeutic advances in gastroenterology2019

Folfirinox

Nicolas Williet, Angélique Saint, Anne-Laure Pointet, David Tougeron, Simon Pernot, Astrid Pozet, Dominique Bechade, Isabelle Trouilloud, Nelson Lourenco, Vincent Hautefeuille and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Nicolas WillietHepatogastroenterology Department, University Hospital of Saint-Etienne, Avenue Albert Raimond, Saint-Etienne 42270, France.ORCID https://orcid.org/0000-0002-7296-5464
Angélique SaintDepartment of Medical Oncology, Antoine Lacassagne Center, Nice, France.
Anne-Laure PointetDepartment of Gastroenterology and Gastro-intestinal Oncology, Hôpital Européen Georges-Pompidou, APHP, Paris Descartes University, Sorbonne Paris Cité, Paris, France.
David TougeronDepartment of Gastroenterology, Poitiers University Hospital, Poitiers, France.
Simon PernotDepartment of GI Oncology, Hôpital Européen Georges-Pompidou, APHP, Paris Descartes University, Sorbonne Paris Cité, Paris, France.
Astrid PozetMethodology and Quality of Life in Oncology Unit (INSERM UMR 1098), University Hospital of Besançon, Besançon, France.
Dominique BechadeDepartment of Medical oncology, Bergonié Institut, Bordeaux, France.
Isabelle TrouilloudDepartment of Medical Oncology, Saint-Antoine Hospital, Paris, France.
Nelson LourencoGastroenterology Unit, Saint-Louis Teaching Hospital, Paris, France.
Vincent HautefeuilleDepartment of Gastroenterology, Amiens-Picardie University Hospital, Amiens, France.
Christophe LocherDepartment of Gastroenterology, CH Meaux, Meaux, France.
Jérome DesrameDepartment of Oncology, Hôpital Privé Jean Mermoz, Lyon, France.
Pascal ArtruDepartment of Oncology, Hôpital Privé Jean Mermoz, Lyon, France.
Anne Thirot BidaultDepartment of Gastroenterology, Hôpital Kremlin Bicêtre, Le Kremlin-Bicêtre, Paris, France.
Bertrand Le RoyDepartment of Digestive and Hepatobiliary Surgery, University Hospital of Saint-Etienne, Saint-Priest-en-Jarez, France.
Denis PezetDepartment of Digestive and Hepatobiliary Surgery, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.
Jean-Marc PhelipDepartment of Hepatogastroenterology, University Hospital of Saint-Etienne, Saint-Etienne, France.
Julien TaiebDepartment of Gastroenterology and Gastro-intestinal Oncology, Hôpital Européen Georges-Pompidou, APHP, Paris Descartes University, Sorbonne Paris Cité, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFolfirinox (FFX) and gemcitabine/nab-paclitaxel (GN) are both standard first-line treatments in patients with metastatic pancreatic cancer (mPC). However, data comparing these two chemotherapeutic regimens and their sequential use remain scarce.

methodsData from two independent cohorts enrolling patients treated with FFX (

resultsIn the whole study population, OS was significantly higher in FFX (14 months; 95% CI: 10-21) than in GN groups (9 months; 95% CI: 8-12) before (

conclusionThis study shows greater OS with FFX than with GN in patients with mPC. GN after FFX failure appears more feasible than the reverse sequence.

Indexed as

Folfirinoxgemcitabine/nab-paclitaxelmetastaticpancreatic adenocarcinomasurvival

Identifiers

PMID31598136
PMCPMC6764033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.